TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties

Leukemia

Volumn 26, Issue 2, 2012, Pages 236-243

  Goh, K C ^a   Novotny Diermayr, V ^a   Hart, S ^a   Ong, L C ^a   Loh, Y K ^a   Cheong, A ^a   Tan, Y C ^a   Hu, C ^a   Jayaraman, R ^a   William, A D ^a   Sun, E T ^a   Dymock, B W ^a   Ong, K H ^b   Ethirajulu, K ^a   Burrows, F ^c   Wood, J M ^a  

^a Singapore Science Park II   (Singapore)

^b TAN TOCK SENG HOSPITAL   (Singapore)

^c Tragara Pharmaceuticals   (United States)

Author keywords

AML; CDK; FLT3; JAK2; multi kinase inhibitor; TG02

Indexed keywords

ANTILEUKEMIC AGENT; CD135 ANTIGEN; CYCLIN DEPENDENT KINASE 2; CYCLIN E; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE 7; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; PROTEIN MCL 1; PROTEIN TYROSINE KINASE INHIBITOR; ROSCOVITINE; STAT5 PROTEIN; SUNITINIB; SYNAPTOPHYSIN; TG 02; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER REGRESSION; CANCER SURVIVAL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VIVO CULTURE; LEUKEMIA; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TREATMENT DURATION; TUMOR XENOGRAFT;

EID: 84860389329     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.218     Document Type: Article

References (27)

1. Baker SJ, Reddy EP. Targeted inhibition of kinases in cancer therapy. Mt Sinai J Med 2010; 77: 573-586.
2. Negrier S, Raymond E. Antiangiogenic treatments and mechanisms of action in renal cell carcinoma. Invest New Drugs 2011, e-pub ahead of print, doi: 10.1007/s10637-10011-19677-10636.
3. Worns MA, Galle PR. Novel inhibitors in development for hepatocellular carcinoma. Expert Opin Investig Drugs 2010; 19: 615-629.
4. Knockaert M, Greengard P, Meijer L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci 2002; 23: 417-425. (Pubitemid 35247771)
5. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006; 24: 1770-1783. (Pubitemid 46628473)
6. Cai D, Latham Jr VM, Zhang X, Shapiro GI. Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells. Cancer Res 2006; 66: 9270-9280. (Pubitemid 44521149)
7. Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci 2004; 117 (Part 8): 1281-1283. (Pubitemid 38559804)
8. Bennett M, Stroncek DF. Recent advances in the bcr-abl negative chronic myeloproliferative diseases. J Transl Med 2006; 4: 41.
9. Tickenbrock L, Muller-Tidow C, Berdel WE, Serve H. Emerging Flt3 kinase inhibitors in the treatment of leukaemia. Expert Opin Emerg Drugs 2006; 11: 153-165.
10. Driggers EM, Hale SP, Lee J, Terrett NK. The exploration of macrocycles for drug discoveryFan underexploited structural class. Nat Rev Drug Discov 2008; 7: 608-624. (Pubitemid 351927725)
11. Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 2009; 8: 547-566.
12. Wernig G, Kharas MG, Okabe R, Moore SA, Leeman DS, Cullen DE et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 2008; 13: 311-320. (Pubitemid 351446195)
13. Atkins M, Jones CA, Kirkpatrick P. Sunitinib maleate. Nat Rev Drug Discov 2006; 5: 279-280.
14. Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, Howard DS, Pettigrew AL et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 2000; 14: 1777-1784.
15. Choudhary C, Brandts C, Schwable J, Tickenbrock L, Sargin B, Ueker A et al. Activation mechanisms of STAT5 by oncogenic Flt3-ITD. Blood 2007; 110: 370-374. (Pubitemid 47026856)
16. Melzner I, Weniger MA, Bucur AJ, Bruderlein S, Dorsch K, Hasel C et al. Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 protein. Int J Cancer 2006; 118: 1941-1944.
17. Uozumi K, Otsuka M, Ohno N, Moriyama T, Suzuki S, Shimotakahara S et al. Establishment and characterization of a new human megakaryoblastic cell line (SET-2) that spontaneously matures to megakaryocytes and produces platelet-like particles. Leukemia 2000; 14: 142-152. (Pubitemid 30068386)
18. Grandage VL, Everington T, Linch DC, Khwaja A. Gö6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells. Br J Haematol 2006; 135: 303-316. (Pubitemid 44484837)
19. Tyner JW, Bumm TG, Deininger J, Wood L, Aichberger KJ, Loriaux MM et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood 2010; 115: 5232-5240.
20. Conroy A, Stockett DE, Walker D, Arkin MR, Hoch U, Fox JA et al. SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples. Cancer Chemother Pharmacol 2009; 64: 723-732.
21. Hannah AL. Kinases as drug discovery targets in hematologic malignancies. Curr Mol Med 2005; 5: 625-642. (Pubitemid 41824226)
22. Ikezoe T, Kojima S, Furihata M, Yang J, Nishioka C, Takeuchi A et al. High levels of p-JAK2 are associated with adverse clinical outcome and can be a molecular target in individuals with acute myelogenous leukemia. Int J Cancer 2011;Epub ahead of print.
23. Ikezoe T, Yang J, Nishioka C, Kojima S, Takeuchi A, Koeffler HP et al. Inhibition of STAT5 by the inhibitor of janus kinases stimulates dormant human leukemia CD34(+)/CD38(+) cells and sensitizes them to anti-leukemia agents. Int J Cancer 2011; 128: 2317-2325.
24. Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007; 7: 673-683. (Pubitemid 47327415)
25. Cai D, Latham Jr VM, Zhang X, Shapiro GI. Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells. Cancer Res 2006; 66: 9270-9280. (Pubitemid 44521149)
26. Pesu M, Candotti F, Husa M, Hofmann SR, Notarangelo LD, O'Shea JJ. Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs. Immunol Rev 2005; 203: 127-142. (Pubitemid 40179698)
27. Verstovsek S, Deeg HJ, Odenike O, Zhu J, Kantarjian HM, Estrov Z et al. Phase 1/2 Study of SB1518, a Novel JAK2/FLT3 Inhibitor, In the Treatment of Primary Myelofibrosis. Blood 2010; 116: Abstract 3082.